SCHEMBL143676

SCHEMBL143676

O=[N+]([O-])c1ccc2nc(Nc3cc(CN4CCOCC4)nc(N[C@H]4CC[C@H](O)CC4)n3)sc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
AHR P35869 1/20 0.53
LCK P06239 14/20 0.53
AURKB Q96GD4 13/20 0.53
ITK Q08881 12/20 0.53
BTK Q06187 2/20 0.51
EGFR P00533 1/20 0.51
INSR P06213 1/20 0.51
SRC P12931 1/20 0.51
TEC P42680 1/20 0.51
TXK P42681 1/20 0.51
BMX P51813 1/20 0.51
LRRK2 Q5S007 1/20 0.51
CAMKK2 Q96RR4 1/20 0.51
IRAK4 Q9NWZ3 1/20 0.51
MAPT P10636 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
HCK P08631 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143677 1.00 ALDH1A1 (0.53) ALDH1A1AHRLCKAURKBITK
SCHEMBL178953 0.87 LCK (0.55) LCKAURKBITKBTKEGFR
SCHEMBL143724 0.87 LCK (0.56) ALDH1A1LCKAURKBITKBTK
SCHEMBL143723 0.87 LCK (0.56) ALDH1A1LCKAURKBITKBTK
SCHEMBL141285 0.84 LCK (0.52) LCKAURKBITKBTKEGFR
SCHEMBL141286 0.84 LCK (0.52) LCKAURKBITKBTKEGFR
SCHEMBL141289 0.83 LCK (0.51) LCKAURKBITKBTKEGFR
SCHEMBL141288 0.83 LCK (0.51) LCKAURKBITKBTKEGFR
SCHEMBL140510 0.83 ITK (0.76) ALDH1A1LCKAURKBITKBTK
SCHEMBL140511 0.83 ITK (0.76) ALDH1A1LCKAURKBITKBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2012-03-08 US disclosed
EP-2408769-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS Glaxo Group Limited (GB) 2012-01-25 EP disclosed
WO-2010106016-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS GLAXO GROUP LIMITED (GB) 2010-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058984-A1 PYRIMIDINE DERIVATIVES USED AS ITK INHIBITORS DTYMK, ITK, DCK ALDH1A1 1469/4885AHR 3620/4885LCK 189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.